RxSight's Q3 2025 performance highlighted strategic initiatives for growth despite a revenue decline, with notable shifts in product mix contributing to improved gross margins.
- Q3 2025 revenue decreased to $30.3 million, down 14% year-over-year and 10% sequentially, largely driven by lower LDD sales.
- LAL revenue grew 6% year-over-year, constituting 85% of total revenue, reflecting strong demand and engagement from ophthalmologists.
- Gross margin improved significantly to 79.9%, benefiting from a higher percentage of LAL sales and reduced unit costs.
- The company narrowed its full-year revenue guidance to $125 million to $130 million, indicating a cautious but optimistic outlook.
- Cash reserves remained stable at $227.5 million, providing a solid foundation for ongoing strategic initiatives and growth plans.
Community Discussion